BBSRC Portfolio Analyser
Award details
The role of the ERK5/BMK1 MAPK pathway in cell growth and oncogenic transformation
Reference
BBS/E/B/52917498
Principal Investigator / Supervisor
Dr Simon Cook
Co-Investigators /
Co-Supervisors
Institution
Babraham Institute
Department
Babraham Institute Department
Funding type
Research
Value (£)
84,795
Status
Completed
Type
Institute Project
Start date
07/11/2000
End date
07/11/2003
Duration
36 months
Abstract
Many cancer cells depend on the ERK1/2 pathway for their continued growth. Consequently many drug companies are trying to fund new inhibitors of this pathway as they may be future drugs for treatment of cancer. Indeed, some drugs have already been described which prevent activation of the ERK1/2 pathway and have desirable biological properties. However, recent studies suggest these drugs may inhibit the related ERK5 pathway. This project aims to determine if that is the case and, if so, if that is a desirable property.
Summary
unavailable
Committee
Not funded via Committee
Research Topics
X – not assigned to a current Research Topic
Research Priority
X – Research Priority information not available
Research Initiative
X - not in an Initiative
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search